Based on our findings, Ga68 PSMA PET/CT for primary staging of prostate cancer may be useful in tumors with a Gleason score greater than 7 or in patients with PSA levels ≥ 10 ng/mL, that is, intermediate or high-risk patients. This evidence concerns the gene KLK3 and prostate cancer.